By Byk-Gulden (now Altana);
The transpulmonary echo contrast agent under development, BY 963, promises to be an excellent ultrasound contrast agent for the noninvasive assessment of left ventricular function. Intravenous administration of BY 963 phospholipid microbubbles improves the reproducibility of e.g. quantitative analysis.

[This entry is marked for removal.]

From POINT Biomedical Corp
BiSphere™ is a technology for drug delivery applications by ultrasound. BiSpheres™ consists of microparticles comprising a shell of an outer layer of a biologically compatible material and an inner layer of biodegradable polymer. The core of the microbubbles contains a filling gas, liquid, or solid for use in drug delivery or as a contrast agent for ultrasonic contrast imaging. The contrast agent particles are capable of passing through the capillary systems of a subject. The drug-loaded biSpheres™ would be administered intravenously and freely circulate throughout the body, while the drug encapsulated within would remain biologically unavailable. The drug would only be released when the biSpheres become flooded when passing through an externally directed ultrasound field.
The use of biSpheres™ to transport agents to specific sites within the body is expected to substantially increase local efficacy while decreasing systemic side effects or adverse reactions. The biSpheres™ may also serve to protect labile agents from metabolism or degradation. The noninvasive release of a protected, encapsulated agent can be controlled by ultrasound imaging to a depth of 20-30 cm from the skin surface.
The flexibility in size control in the biSphere™ technology has enabled the construction of submicron ultrasound contrast agents suitable for lymphatic imaging, with a diameter in the submicron range. This agent, while much smaller in size than CardioSphere®, is based on the BiSphere configuration: a shell within a shell enclosing a gas. The inner layer, made from a biodegradable polymer, provides the physical structure and controls the acoustic response. The outer layer functions as the biological interface. Each of these layers has been independently tailored to fulfill the specific requirements for lymphatic imaging.

Bubble specific imaging methods rely usually on non-linear imaging modes. These contrast imaging techniques are designed to suppress the echo from tissue in relation to that from a microbubble contrast agent.
Stimulated acoustic emission (SAE) and phase / pulse inversion imaging mode (PIM) are bubble specific modes, which can image the tissue specific phase.
In SAE mode bubble rupture is seen as a transient bright signal in B-mode and as a characteristic mosaic-like effect in velocity 2D color Doppler.
PIM are Doppler modes and detect non-linear echoes from microbubbles. In pulse inversion imaging modes the transducer bandwidth extends, resulting in improved spatial resolution and more contrast.

See also Contrast Pulse Sequencing, Microbubble Scanner Modification, Narrow Bandwidth, Contrast Medium, Dead Zone.

Cerebrovascular ultrasonography is the best screening tool for the detection of carotid artery stenosis. Transcranial sonography is used in the evaluation of patients with suspected cerebrovascular disease, but a common problem is the attenuation of the ultrasound signal by the skull.
Contrast enhanced ultrasound play a particularly important role in the visualization of the intracranial vessels, and thus improves the accuracy of transcranial Doppler and increases the potential of this technique. The use of microbubbles is helpful for classification of stenosis and for plaque evaluation in patients with poor initial examination. Ultrasound contrast agents avoid misdiagnosing a subtotal stenosis, which is a very important clinical issue.

See also Adventitia, Intima, Periorbital Doppler, and Acoustic Window.

From Lantheus Medical Imaging.
Activated DEFINITY® Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.
Echocardiography with Definity produced more detailed images of the heart in difficult-to-image patients versus echocardiography alone, and images obtained with the contrast agent provided a more accurate assessment of segmental wall motion compared with unenhanced images.

See also Coherent Contrast Imaging.

In August 2001 DuPont Pharmaceuticals Company received FDA approval.